Statistics
The Climb Bio stock price is currently $ 10.36 with a total market cap valuation of $ 608.53M (58.74M shares outstanding). The Climb Bio is trading on NASDAQ under the ticker sign CLYM. Climb Bio price is up
Description
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Company Profile
- Full Name: Climb Bio
- Sector: Healthcare
- Website: https://eliemtx.com
